Argonaute (Ago) 2 is the catalytic engine of mammalian RNA interference, but little is known concerning the regulation of Ago2 by cell-signaling pathways. In this study we show that expression of Ago2, but not Ago1, Ago3, or Ago4, is elevated in estrogen receptor (ER) ␣-negative (ER␣ Ϫ )
M
icro-RNAs (miRNAs) are small (19 -24 nucleotide) noncoding RNAs that mediate posttranscriptional gene silencing through specific base pairing with target mRNAs. Once precursor miRNAs are processed and exported to the cytosol, one strand of the resulting miRNA duplex (guide strand) is incorporated into Argonaute (Ago)-containing ribonucleoprotein complexes (1) (2) (3) . These complexes are then directed to the 3Ј-untranslated region (UTR) of target mRNAs where imperfect base pairing to the respective miRNA induces gene silencing via translational repression or mRNA cleavage/destabilization (4) (5) (6) . The process of mRNA cleavage is mediated by the endonuclease activity of Ago2 containing ribonucleoprotein complexes (7) (8) (9) .
Ago2 is a member of a family of eight proteins in mammals, four of which are germ line specific (10) . Ago proteins contain a P-element induced wimpy testis (PIWI) domain that can adopt a ribonuclease H fold with potentially innate endonuclease activity (11) (12) (13) (14) . However, Ago2 is the only Ago protein shown to mediate miRNA-dependent cleavage/degradation of target mRNAs in mammals. Recently, studies have also implicated functional roles for Ago2 independent of its endonuclease activity (15) (16) (17) (18) (19) . Ago2 has been observed as diffuse within the cytoplasm, and localized to both processing bodies (P bodies) and the nucleus (20) .
Recent studies indicate that Ago2 is required for a variety of developmental processes that occur in a tissue-specific manner. For instance, Ago2-null mice are embryonic lethal, potentially due to neural tube defects (12, 21) . Disruption of Ago2 leads to gastrulation arrest and uncontrolled mesoderm expansion in mice through overactive Fgf8 signaling (22) . Ago2 also plays a role in hematopoiesis because bone marrow conditional Ago2 Ϫ/Ϫ mice have defective B-cell differentiation (23) . Given these findings, the fact that no functional redundancy exists between Ago2 and other Ago paralogs highlights the importance of Ago2-miRNA complexes within various developmental processes (24) . Recently, microarray expression studies have indicated that genes involved in miRNA biogenesis are dysregulated in various breast tumor types (25, 26) . In particular, expression of Ago2 is elevated in the estrogen receptor (ER) ␣-negative (ER␣ Ϫ )
ERBB2-negative [human epidermal growth factor receptor 2-negative (HER2 Ϫ )] epidermal growth factor (EGF) receptorpositive (EGFR ϩ ) basal-like breast tumor subtype. Furthermore, Ago2 expression also negatively correlates with ER␣ status in gene profiling studies performed on various breast tumor samples (27) . Although these studies implicate Ago2 in more aggressive breast tumor types, to date no studies have determined whether Ago2 is involved specifically in the tumorigenic process. Breast cancer is the second-leading cause of cancer-related deaths among women in the United States, and approximately one third of invasive breast carcinomas will be diagnosed as ER␣ Ϫ (28, 29) . In patients with ER␣ Ϫ breast tumors, treatment options are limited because established antihormone adjuvant therapies (i.e. tamoxifen and CYP19-aromatase inhibitors) are ineffective at ablating tumor growth (30) . In addition, this tumor type is more transformed and proliferates independent of estrogenic-stimulated signaling, leading to poor clinical outcomes (29, 30) . Transcriptional profiling has allowed for the categorization of breast cancer into several subtypes. The two main ER␣ Ϫ subtypes are designated as either "basal-like" or "HER2,"
which frequently overexpress the EGFR or the related ERRB2/ HER2 protein, respectively. In this study we demonstrate that Ago2 is up-regulated by an EGFR/MAPK signaling pathway in ER␣ Ϫ breast cancer cell lines, whereas overexpression of Ago2 is sufficient to drive breast tumor progression in the ER␣ ϩ MCF-7 human breast adenocarcinoma cell line.
Materials and Methods

Cell lines and tissue samples
Tissue culture reagents were purchased from Invitrogen Corp. (Carlsbad, CA) and Sigma-Aldrich Corp. (St. Louis, MO). All breast cancer cell lines were obtained through American Type Culture Collection (Manassas, VA). Cell lines were maintained in DMEM/F12 supplemented with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin for standard culture (serum). Cells cultured in hormone-depleted media (HDM) were grown with media supplemented with 10% charcoal-treated dextran-stripped FBS (HyClone, Logan, UT). Stably transfected cells were maintained in DMEM/F12, 10% FBS, and 250 g/ml G418.
Human primary breast carcinomas (Ն1.5 cm) were obtained from consenting patients under an institutional review board approved protocol within 5 min of surgical resection, and frozen in optimal cutting temperature media at Ϫ80 C. Cryosections were evaluated for areas of high tumor cell density via hematoxylin and eosin stain. Tissue cores were obtained with a 2-mm dermal punch, harvested for RNA via the RNAeasy Kit from QIAGEN, Inc. (Valencia, CA), and processed for reverse transcription and hybridization to Illumina's Human-8 cDNA array according to the manufacturer's protocol (Illumina Inc., San Diego, CA). Gene expression analysis was performed with Bead Studio software from Illumina using Rank invariant normalization. Individual gene values were used only if multiple probe signals had P values less than 0.05.
Luciferase reporter assays
Firefly luciferase reporter assays for miR-206 activity were performed on breast cancer cell lines essentially as described (31) . Luciferase activity generated from the pIS-ER␣-1 constructs were measured using the dual-luciferase reporter assay system in combination with a Renilla luciferase construct (pRL-TK), to control for transfection efficiency, from Promega Corp. (Madison, WI). Results were reported as the average relative luciferase activity from three independent experiments normalized to Renilla activity Ϯ SEM.
Chemical inhibitor and small interfering RNA (siRNA) treatments
Breast cancer cell lines were treated with various hormones and selective inhibitors, purchased from Tocris Bioscience (Ellisville, MO). Cells at 80% confluence were washed and switched to drug-containing media, which included 17␤-estradiol (E 2 ), propyl pyrazole triol (PPT), diarylpropionitrile (DPN), U0124, U0126, and/or EGF (Sigma-Aldrich). After 24 h cells were washed and retreated with the appropriate drug so cumulative effects could be determined at 48 h. Treatment duration was 12 h during studies using the MG132 compound. For siRNA experiments, MDA-MB-231 cells were transfected with EGFR siRNA (Dharmacon, Inc., Lafayette, CO), and protein lysates were isolated after 24 h.
Cycloheximide (CHX) stability studies
MDA-MB-231 cells at 80% confluency were treated with 200 M CHX (Sigma-Aldrich) for 30 min (zero time point). Cells were then treated with 100 ng/ml EGF, 10 M U0126, 10 M PD153035, or any combination of the aforementioned, plus 200 M CHX. At each time point (0, 0.5, 3, and 6 h) after drug treatments, cells were harvested for protein in 250 l radioimmunoprecipitation assay (RIPA) buffer/ well. Western blot analysis was performed on 15 l sample, and densitometry readings of the Ago2-specific band were reported. These values were normalized to amount loaded on the gel, which is equivalent to total cell number, and reported as the mean of three independent experiments Ϯ SEM.
Quantitative real-time PCR detection assay
For mRNA and miRNA detection, real-time PCR assays were performed on 100 ng/l total RNA isolated from various cell lines and treatment conditions, using TRIZOL reagent from Invitrogen, as previously described (31) . Primers used in this study are described in supplemental Table  S1 , which is published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org. Data were analyzed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA) and Microsoft Excel (Microsoft Corp., Redmond, WA). All experiments were performed in quadruplicate and normalized to either RPL-19 or 5s RNA. In some instances end-point RT-PCR assays were performed. For these assays the PCR products were resolved on a 2% agarose gel and detected by ethidium bromide.
Western blot analysis
Western blot analyses were performed essentially as described (31) . Antibodies to Ago2 
Generation of the MCF-7-Ago2 transfectants
All basic molecular biology and transfection reagents used to make the MCF-7-Ago2 transfectants were obtained from Invitrogen. MCF-7 cells were cultured to 90% confluency and transfected with pcDNA 3.1 expression constructs harboring either full-length Ago2 [MCF7-Ago2-wild type (WT)] or N-terminal-truncated mutant Ago2 (MCF-7-Ago2_167C and MCF-7-Ago2_408C) myc-tagged cDNAs (32) , or pcDNA 3.1 alone (MCF-7-empty) as a control. After 24 h, cells were washed and cultured in medium containing 850 g/ml G418 every 48 h for 3 wk. After selection, each pool of cells, five from each cell type/transfectant, were trypsinized and cultured in a six-well plate containing medium plus 250 g/ml G418. The pooled transfectants were screened for Ago2 and myc-tagged expression by real-time PCR and Western blot analyses. Transfectants with 2-fold or more enrichment in Ago2 over parental MCF-7 cells (MCF-7-Par) were classified as Ago2 high and characterized.
Trypan blue proliferation assays
The Trypan blue viability assays were performed on the five MCF-7 cell transfectants over the course of 96 h. After seeding in 12-well culture plates at 3 ϫ 10 4 cells per well, the number of viable cells were determined every 24 h by trypsinization of cells, resuspension in growth medium, 1:4 dilution with 0.4% Trypan blue stain, and hemocytometer counts. Values generated are representative of three independent experiments and are reported as the average viable cell number Ϯ SEM.
Homotypic aggregation assay
Breast cancer cells and transfectants (1 ϫ 10 5 ) were transferred to 1.5-ml microcentrifuge tubes containing 1 ml culture medium. Each tube was incubated at 37 C for 0.5 h with 0.5 l 2 mg/ml Calcein-AM (Invitrogen). Samples were centrifuged at 460 ϫ g for 10 min, washed with PBS, resuspended in 1 ml culture medium, and placed on a rocker for 1.5 h at 37 C. Five hundred microliters of 3.75% formaldehyde were added to each tube, and the cell mixture was transferred to three wells within a 12-well culture dish. Fluorescent and phase-contrast images of cell aggregates were obtained using a Zeiss Stemi SV11 stereomicroscope with an AttoArc HBO 100W power source (Carl Zeiss MicroImaging, Inc., Thornwood, NY), whereas quantification of aggregates was measured using a hemocytometer, where all nine grids were counted.
Wound healing/migration assay
Various breast cancer cells and transfectants were seeded into 24-well plates. Once cells reached confluence, a wound was made in the center of each well using a 200-l pipette tip. At each time point after wound formation, cells were washed with PBS, fixed in 100% methanol, rinsed with PBS, and stained with 1% crystal violet. Images of each wound were captured on a Zeiss SV11 stereomicroscope from Carl Zeiss MicroImaging and imported into Adobe Photoshop 8.0 (Adobe Systems, Inc., San Jose, CA). Using the measure tool within the software, five measurements were taken of the distance between the two migrating fronts. Data were recorded as width of wound (mm) Ϯ SEM.
Statistical analysis
Values reported in all analyses were expressed as the mean Ϯ SEM, and densitometry readings from Western blots were reported as averages. Differences between treatments and/or groups were analyzed by ANOVA with either a Dunnett or Bonferroni multiple comparison after test using GraphPad Instat Software 3.0. Statistical significance was accepted at P Ͻ 0.05. Furthermore, expression of Ago1, Ago3, and Ago4 did not change within these tumors. Collectively, these findings demonstrate that Ago2 is selectively dysregulated between two breast tumor subtypes.
Results
Ago2
One hypothesis formed from these findings was that ER␣/ estrogen signaling suppressed Ago2 expression. However, E 2 and the ER␣-selective agonist, PPT, enhanced Ago2 levels in hormone-depleted MCF-7 cells (Fig. 1D) .
Inhibition of EGFR/MAPK signaling reduces Ago2 expression in ER␣
؊ breast cancer cells
Two mechanisms by which Ago2 could be up-regulated in the ER␣ Ϫ breast cancer cells are through gene amplification and/or constitutive activation of a cell-signaling cascade. Semiquantitative end-point PCR performed on genomic DNA isolated from the four breast cancer cell lines revealed no evidence indicative of Ago2 gene amplification (data not shown). EGFR and the MAPK signaling cascade represent a major class of signal transduction pathways in ER␣ Ϫ breast cancers (33) (34) (35) (36) . To determine whether EGFR is required for Ago2 protein expression, Western blot experiments were performed on MDA-MB-231 cells treated with EGFR siRNA in the presence of serum-containing growth medium. After 24 h 100 nM small interfering EGFR (siEGFR) treatment, Ago2 expression was reduced 9.1 Ϯ 0.25-fold, whereas ␤-actin and ER␤ expression remained constant ( Fig. 2A) . Similarly, 100 ng/ml EGF for 48 h elevated Ago2 mRNA and protein levels approximately 1.5-fold (Fig. 3A) .
To ascertain whether EGF stimulated Ago2 expression through the MAPK pathway, ER␣ Ϫ breast cancer cells were treated with U0126, a MAPK kinase (MEK) inhibitor, or U0124, an inactive U0126 analog. Western blot analyses indicated that the U0124 compound had no effect on Ago2 protein levels, whereas, 48 h 10 M U0126 treatment decreased Ago2 expression to nondetectable levels (Fig. 2B ). Real-time PCR analysis of dose-response experiments indicated that 10 M U0126 significantly reduced Ago2 transcript levels after 48 h by 3.3 Ϯ 0.15-fold and 2.5 Ϯ 0.21-fold in MDA-MB-231 and MDA-MB-435 cells, respectively (Fig. 2C) . The effect of U0126 was specific, in that RPL-19 and Ago1 mRNA levels remained unchanged. In MDA-MB-231 cells, Ago2 mRNA levels were the same after treatment with either 100 ng/ml EGF plus 10 M U0126, or with U0126 alone (Fig. 3A, left panel) . These data indicate that the MAPK pathway serves as the primary mediator of EGF-stimulated induction of Ago2 gene expression in ER␣ Ϫ cells.
EGF enhances Ago2 protein stability through MAPK signaling in MDA-MB-231 cell lines
Results from Western blot analyses of the experiments described previously revealed that Ago2 protein expression did not correlate with transcript levels under certain conditions. Specifically, 100 ng/ml EGF plus 10 M U0126 enhanced Ago2 expression at the protein level, but not at the mRNA level, compared with U0126 alone (Fig. 3A) . Previous studies have shown that EGF, via EGFR, can promote protein stability through phosphorylation and/or the prevention of ubiquitin-mediated proteasomal degradation (37) (38) (39) (40) (41) . To test the notion that Ago2 protein levels are regulated by the proteasome, we treated MDA-MB-231 cells with 10 M MG132, a proteasomal inhibitor (Fig.  3B ). Twelve hours after MG132 treatment, Ago2 protein levels were enhanced approximately 3.1-fold in cells pretreated with or without 10 M U0126. These data indicate that in ER␣ Ϫ cells, EGF enhances Ago2 stability posttranslationally.
To test further that EGF-EGFR signaling increases Ago2 protein stability, CHX half-life studies were performed on EGF and/or U0126 treated MDA-MB-231 cells. After 6 h, Ago2 was reduced 2.5 Ϯ 0.14-fold in CHX plus U0126 treated samples when compared with the CHX alone control (Fig. 3C) . This reduction was ablated by 1.7 Ϯ 0.12-fold in CHX, U0126, and EGF treated cells. The use of 10 M PD153035, an EGFR inhibitor, confirmed that the loss of EGFR signaling leads to an immediate reduction, 1.7 Ϯ 0.11-fold by 0.5 h, in Ago2 stability. These findings indicate that EGFR signaling, through an as of yet unidentified pathway, is essential for maintaining Ago2 protein expression and stability in MDA-MB-231 cells.
Generation and characterization of the Ago2 overexpressing (MCF-7-Ago2-WT) cell types
Because Ago2 is regulated by an oncogenic signaling cascade in ER␣ Ϫ cells, we examined whether increased Ago2 expression induced a transformed phenotype. Ago2 was stably overexpressed in the less transformed ER␣ ϩ MCF-7 cell line as described in Materials and Methods. For each of the Ago2 cell types generated, three of the five pooled MCF-7 cell transfectants were classified as having Ago2 high expression (Fig. 4A) . Specifically, MCF-7-Ago2-WT transfectants had 2.5 Ϯ 0.11-fold and 2.9 Ϯ 0.18-fold greater Ago2 mRNA and protein levels, respectively, compared with MCF-7-Par cells. Because the Ago2 antibody used in these screening experiments recognized the N-terminal region of Ago2, expression of the Ago2 N-terminal deletion mutants in the MCF-7 cells were determined by c-myc epitope-tag expression and Ago2 mRNA levels. Our analysis indicated that MCF-7-Ago2 mutants expressed Ago2 at levels comparable to the MCF-7-Ago2-WT cell types.
We previously showed that miR-206 targets two sites (ER␣-1 and ER␣-2) within the 3Ј-UTR of the ER␣ mRNA (31). This was done by insertion of each predicted site into the 3Ј-UTR of the pIS-0 luciferase reporter construct. We also observed that miR-206 induced degradation of pIS-ER␣-1 luciferase mRNA only in cells that contained endogenous Ago2 (supplemental Fig. S1 ). Based on these findings, cells that overexpress Ago2 protein would presumably have enhanced miR-206 activity. To test this, pIS-ER␣-1 constructs were transiently transfected into the five MCF-7 cell types for 24 h to determine their miR-206 activity (Fig. 4B, left panel) . In the MCF-7-Ago2-WT cells, miR-206 activity on pIS-ER␣-1-WT and pIS-ER␣-1-single nucleotide polymorphism constructs were enhanced by 1.3 Ϯ 0.12-fold and 2.1 Ϯ 0.13-fold, respectively, when compared with MCF-7-Par cells. No change in miR-206 activity was observed in cells transfected with the pIS-ER␣-1-5Ј mutant construct, or with any construct used in the MCF-7-empty and MCF-7-Ago2 mutant transfectants. Realtime PCR experiments on the five MCF-7 cell types confirmed that these results were due to changes in Ago2 expression and not miR-206 levels (Fig. 4B, right panel) . Thus, MCF-7-Ago2 cells express elevated levels of functional Ago2, which correlates with enhanced miR-206 activity.
Elevated Ago2 levels did not result in reduced ER␣ expression (Fig. 4B, bottom panel) . In fact, MCF-7-Ago2-WT transfectants had elevated ER␣ protein levels. This is discordant with the finding that Ago2 overexpression resulted in elevated activity of a miRNA, miR-206, that targets ER␣, and indicates that there is a greater concentration of miRNAs that target proteins involved in ER␣ suppression than those that target ER␣ itself.
Trypan blue proliferation assays performed on the various MCF-7 transfectants indicated that after 96 h, the number of viable MCF-7-Ago2-WT cells was 1.9 Ϯ 0.14-fold greater than the other four MCF-7 cell types (Fig. 4C) . Further evidence of enhanced proliferation was obtained by Western blot analysis for the expression of Ki67 antigen, a cell-cycle related nuclear protein (Fig. 4D) . The levels of Ki67 were enhanced 2.5 Ϯ 0.12-fold in the MCF-7-Ago2-WT transfectants when compared with the other MCF-7 cell types. These findings suggest that the expression of functional Ago2 protein (i.e. miRNA-responsive) stimulates cell cycle progression in MCF-7 cells.
MDA-231 Cells R e l a t i v e m R N A Expression
Ago2 expression correlates with a scattered phenotype and promotes loss of cell adhesion
In addition to enhanced proliferation, the MCF-7-Ago2-WT transfectants displayed a distinct "scattered" phenotype not shared by any other MCF-7 cell type. Because MCF-7 cells normally grow in tight colonies, this "scattered" phenotype is indicative of reduced cell-cell adhesion. Homotypic aggregation assays performed to measure this reduction of functional cell-cell adhesion revealed that parental MCF-7, MCF-7-Ago2 mutant, and MCF-7-empty cell types readily formed cell aggregates, whereas the MCF-7-Ago2-WT cells mimicked the phenotype of the nonadherent MDA-MB-231 cells (Fig. 5A, top  panel) . This finding was verified using Calcein-AM, a fluorescent dye retained in metabolically active cells (Fig. 5A, bottom panel) . To quantify the extent of cell aggregation, the number of aggregates was measured via Trypan blue exclusion and counted on a hemocytometer. On average, MCF-7-Ago2-WT cells generated half the number of aggregates compared with parental, empty vector control, or Ago mutant cells (6.3 ϫ 10 3 Ϯ 0.98 ϫ 10 3 vs. ϳ11.6 ϫ 10 3 Ϯ 0.88 ϫ 10 3 ; P Ͻ 0.05), respectively. These results indicate the loss of cell-cell adhesion molecules in the MCF-7-Ago2-WT transfectants, which is an indicator of tumorigenic transformation.
Functional cell-cell adhesion requires the coordinated regulation of a variety of adhesion molecules and associated structural, scaffolding, and signaling proteins. Therefore, Ago2 may be involved in directly silencing the E-cadherin cell-cell adhesion complex in MCF-7 cells. Real-time PCR assays indicated that ␤-actin, E-cadherin, vinculin, and ␤-catenin mRNA levels were reduced between 1.5-to 4.1-fold in MCF-7-Ago2-WT cells when compared with the other MCF-7 cell types (Fig. 5B) . These values were normalized to RPL-19, which remained constant in all five cell types. Western blot analyses performed on the five MCF-7 cell types indicated that ␤-actin, E-cadherin, and ␤-catenin expression were reduced by 2.1 Ϯ 0.12, 1.5 Ϯ 0.14, and 1.6 Ϯ 0.13-fold in the MCF-7-Ago2-WT cells, respectively, whereas tubulin remained unchanged (Fig. 5C ). These data support the notion that functional Ago2 can dysregulate functional protein complexes by silencing the key proteins within a given pathway. 
Overexpression of Ago2 in MCF-7 cell lines enhances their migratory/invasive properties
Although MCF-7 cells generally have poor invasive capabilities, the MCF-7-Ago2-WT cells had a transformed phenotype similar to the MDA-MB-231 cell line. To test whether Ago2 might enhance the migratory/invasive capabilities of the MCF-7 cell type, wound healing assays were performed over the course of 24 h (Table 1) . MDA-MB-231 cells quickly occupied the wound by 72.8 Ϯ 8.12% over the course of 24 h, whereas parental MCF-7 cells invaded the wound by only 14.1 Ϯ 2.31%. However, the MCF-7-Ago2-WT transfectants were able to infiltrate significantly the wound area by 35.9 Ϯ 4.56%, compared with the MCF-7-empty transfectants, which only had 17.9 Ϯ 3.54% wound closure. This migratory phenotype was not observed in the MCF-7-Ago2_167C and MCF-7-Ago2_408C mutant transfectants. These data indicate that Ago2 enhances the migratory capabilities of MCF-7 breast cancer cells, potentially by enhancing the miRNA activity within this cell type.
Discussion
miRNAs have emerged as critical factors in the regulation of tumorigenesis. Some miRNAs (e.g. miR-21) are oncogenic, whereas others (e.g. let-7) function as tumor suppressors (42) . Numerous miRNAs are differentially expressed in breast tumors. Some of these have been linked to general aspects of breast cancer biology (e.g. cell cycle traverse, metastasis, and apoptosis), and a smaller percentage has been identified as regulators of specific mRNAs in breast cancer cells (e.g. ER␣, programmed cell death 4 protein, and HER2) (31, (43) (44) (45) . Despite the broad range of miRNA-induced phenotypes, all miRNAs studied to date assemble into Ago-miRNAcontaining ribonucleoprotein complexes (7). It has also been shown that a subset of miRNA/mRNA hybrids containing imperfect base pairing can lead to the degradation of the targeted mRNA (46, 47) . Due to its innate catalytic slicer activity, the cleavage/degradation of target mRNAs by a miRNA requires Ago2 (7, 12) . As such, this unique action confers a centrally important role upon Ago2 in the biology of normal and transformed cells. Nevertheless, the study of whether the expression of Ago2 itself is regulated, and how changes in Ago2 expression impact normal physiology, development, and tumorigenesis, has largely remained unstudied.
The first major finding of this study was that mRNA levels of Ago2, but not of Agos 1, 3, or 4, were markedly elevated in ER␣ Therefore, transcriptional regulation of the Ago2 gene appears to require intact MAPK signaling downstream of EGFR. A recent transcriptional profiling study described the presence of a "MAPK signature" in breast cancer cells (50) . This consisted of a subset of approximately 400 genes, whose transcription was either up-regulated or down-regulated by stable overexpression of EGFR, or constitutively active Erbb2, Raf, or MEK, in MCF-7 cells. We propose that Ago2 is a centrally important component of the "MAPK signature" in breast cancer cells, whose up-regulation is likely to affect the expression of numerous mRNAs through miRNA/Ago2-dependent mechanisms. Future studies will be aimed at the characterization of transcription factors downstream of the MAPK pathway (e.g. Ets, Jun/Fos) and their interaction with the promoter region of the Ago2 gene. Combined U0126 and EGF treatments along with MG132 studies indicated that stabilization of Ago2 protein levels are determined, in part, by ubiquitination and proteasomal degradation. EGFR signaling has modified the stability of specific proteins via posttranslational mechanisms (51, 52) . Our findings suggest that a specific E3 ubiquitin ligase, acting as a tumor suppressor, targets Ago2 in an EGF-suppressible manner. Several E3 ligases have been implicated in breast cancer, both as oncogenes and tumor suppressors (53, 54) . Thus, Ago2 may be targeted by a breast cancer-related tumor-suppressive E3 ligase, such as BRCA1/BARD1 or CHIP, or by one of the over 500 E3 ligases currently identified.
Alternatively, EGF may increase the biological half-life of Ago2 through an effect on its subcellular localization. A recent study by Zeng et al. (55) demonstrated that Ago2 is phosphorylated on Ser-387 by p38 MAPK, which induced Ago2 localization to P bodies. If, in fact, EGF/MAPK signaling has a similar effect on Ago2, the sequestration to P bodies may contribute to an increased stability of the enzyme.
The third major finding of this study was that moderate overexpression of Ago2 produced a more transformed, less epitheliallike phenotype in MCF-7 cells. We also expressed two Ago2 mutant constructs that generate proteins incapable of mediating miRNA-dependent functions (32) . Mutant MCF-7-Ago2_167C and MCF-7-Ago2_ 408C cells, expressed both myc-tagged Ago2 proteins and total (endogenous and exogenous) Ago2 mRNA levels comparable to the MCF-7-Ago-WT cells. In a previous study, we determined the efficiency of miR-206 to target ER␣ using heterologous luciferase reporters harboring two miR-206 target sites within the ER␣ 3Ј-UTR (31) . Similar luciferase assays in the various MCF-7-Ago2 transfectants showed that the activity of miR-206 was elevated in MCF-7-Ago2-WT transfectants but remained unchanged in the MCF-7-Ago2 mutant cells. Despite the change in miR-206 activity, mature miR-206 levels remained constant within all MCF-7 cell types. This finding provides evidence that formation of Ago2-miRNA-containing ribonucleoprotein complexes are the rate-limiting factor for miR-206 function within MCF-7 cells, and emphasizes that the relative levels of a miRNA are not the sole determinant of activity.
Two hallmarks of enhanced tumorigenic progression of epithelial cells are the loss of cell-cell adhesion and enhanced cell motility. Both processes contribute to a transformed phenotype that resembles the epithelial-to-mesenchymal transition during development (56) (57) (58) . MCF-7 cells are poorly tumorigenic in xenograft models, maintain an epithelial-like phenotype due to the presence of cell-cell adhesion molecules, grow in tight colonies, and are weakly motile. In contrast, MCF-7-Ago2-WT cells have a "scattered" phenotype reminiscent of the epithelial-tomesenchymal transition process noted previously. This includes reduced cell-cell adhesion, lower levels of the adhesion molecules E-cadherin and ␤-catenin, and a greater degree of migratory capabilities as measured by the wound healing assay. Because none of the MCF-7-Ago2 mutant cells displayed these transformed phenotypes, the aforementioned findings indicate that enhanced Ago2 expression, along with increased miRNA activity, contribute to the greater degree of transformation within this cell type.
An unexpected finding was that elevated Ago2 associated with increased endogenous ER␣. This suggests that miRNAs in MCF-7 cells actively target proteins involved in the suppression of ER␣ expression and/or promotion of the degradation of ER␣ protein. This enrichment in ER␣ may also aid in the transformation of the Ago2 transfectants.
Given the complexity of miRNA-mRNA interactions, it is surprising to observe such a clear phenotypical shift toward increased transformation in the Ago2 transfectants. One explanation may lie within the role of miRNAs to dampen transcriptional noise and stochastic variations in mRNAs and corresponding proteins that play a role in the differentiated function of a cell (59) . At low levels, Ago2 would allow for such dampening and promote stability of a differentiated phenotype. However, upon elevation of Ago2, the "homeostatic" miRNAs could suppress those transcripts involved in a differentiated phenotype to an inappropriately low level, allowing oncogenic pathways to predominate. Ago2 could also promote transformation through miRNA-independent mechanisms. Further work is needed to profile miRNAs and characterize their targets/ physiological roles to test this supposition.
